Bio-Rad Laboratories Inc. 01.23.17
Bio-Rad Laboratories Inc., a global provider of life science research and clinical diagnostic products, is purchasing RainDance Technologies Inc. Terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during the first quarter of 2017.
RainDance Technologies’ foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.
“We are pleased to have RainDance join Bio-Rad,” said Norman Schwartz, Bio-Rad president and CEO. “The company’s droplet-based solutions will extend our reach into next generation sequencing applications and strengthen our position in the area of Droplet Digital PCR. We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications.”
Based in Billerica, Mass., RainDance Technologies offers a proprietary droplet technology that enables research in areas such as non-invasive liquid biopsy. These ultra-sensitive genomic tools that include RainDrop Digital PCR, ThunderStorm, and ThunderBolts Next-Generation Sequencing Enrichment, offer accurate, reliable, and cost-effective detection of genetic variations in cancer as well as inherited and infectious diseases. RainDance customers include research institutions and laboratories around the world.
Bio-Rad Laboratories Inc. develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostic markets. Founded in 1952, Bio-Rad is based in Hercules, Calif., and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had more than $2.1 billion in revenues in 2015.
RainDance Technologies’ foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.
“We are pleased to have RainDance join Bio-Rad,” said Norman Schwartz, Bio-Rad president and CEO. “The company’s droplet-based solutions will extend our reach into next generation sequencing applications and strengthen our position in the area of Droplet Digital PCR. We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications.”
Based in Billerica, Mass., RainDance Technologies offers a proprietary droplet technology that enables research in areas such as non-invasive liquid biopsy. These ultra-sensitive genomic tools that include RainDrop Digital PCR, ThunderStorm, and ThunderBolts Next-Generation Sequencing Enrichment, offer accurate, reliable, and cost-effective detection of genetic variations in cancer as well as inherited and infectious diseases. RainDance customers include research institutions and laboratories around the world.
Bio-Rad Laboratories Inc. develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostic markets. Founded in 1952, Bio-Rad is based in Hercules, Calif., and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had more than $2.1 billion in revenues in 2015.